Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1637 1656 1681 1682 1699
This examiner grants 55% of resolved cases
Tian Nmn Yu has resolved 89 cases within Art Unit 1634 of Technology Center 1600. The examiner has an allowance rate of 55.1 percent, showing the distribution between grants and abandonments. The median days to allowance is 1399, which provides a benchmark for the duration of the prosecution phase. The interview lift of 20.4 percent indicates that verbal discussions are a method for overcoming rejections.
For applicants in the 1600 tech center, this lift suggests that the examiner is receptive to technical arguments presented during interviews. Strategic use of interviews may help navigate the 1399-day path to a patent grant. With 89 cases resolved, the data provides a look at the examiner's habits. The 55.1 percent allowance rate suggests that success is achievable through diligent prosecution. The 20.4 percent lift is a tool for practitioners to consider when planning their strategy for this specific art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19449295 | DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS | Non-Final OA | Natera, Inc. |
| 18038454 | GRAPHENE-BASED BIOSENSOR AND DETECTION METHOD USING SAME | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17260611 | POLYNUCLEOTIDE SYNTHESIS METHOD, KIT AND SYSTEM | Final Rejection | Oxford Nanopore Technologies PLC |
| 18718585 | Single-Cell Epigenomic Profiling Using Droplet Fluidics and Hydrogels | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18169681 | EFFICIENT SCREENING LIBRARY PREPARATION | Non-Final OA | The Regents of the University of California |
| 17625687 | LIPID-MODIFIED OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18631875 | COMPOSITIONS AND METHODS FOR HLA HAPLOTYPE SEQUENCING | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18704416 | MANIPULATING AND DETECTING BIOLOGICAL SAMPLES | Non-Final OA | Singular Genomics Systems, Inc. |
| 17531488 | CONTACTLESS DETECTION OF AN ABERRANT CONDITION | Non-Final OA | Singular Genomics Systems, Inc. |
| 18677551 | ANALYSIS METHOD | Non-Final OA | Denso Corporation |
| 18275797 | MICRO RNA LIVER CANCER MARKERS AND USES THEREOF | Non-Final OA | THE CLEVELAND CLINIC FOUNDATION |
| 17373653 | cDNA SPIKE-IN CONTROL FOR SINGLE CELL ANALYSIS | Non-Final OA | Becton, Dickinson and Company |
| 18620056 | METHODS FOR EARLY DETECTION OF CANCER | Non-Final OA | GUARDANT HEALTH, INC. |
| 18325759 | COMPOSITIONS AND METHODS FOR ENRICHING METHYLATED POLYNUCLEOTIDES | Final Rejection | GUARDANT HEALTH, INC. |
| 17619154 | METHOD FOR DIAGNOSIS OF EARLY AGEING OF THE SKIN | Non-Final OA | L'OREAL |
| 18361763 | METHOD OF DETECTING MULTIPLE FORMS OF AN ANALYTE | Final Rejection | GEN-PROBE INCORPORATED |
| 17928452 | USE OF MICROVESICLE SIGNATURE FOR THE DIAGNOSIS AND TREATMENT OF KIDNEY TRANSPLANT REJECTION | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 17651135 | SINGLE TUBE PREPARATION OF DNA AND RNA FOR SEQUENCING | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 18570947 | NUCLEIC ACID NANOPORE WITH ENHANCED SENSING FUNCTIONALITY | Non-Final OA | UCL BUSINESS LTD |
| 18570381 | DETECTION OF MULTIPLE TARGET NUCLEIC ACID USING MULTIPLE DETECTION TEMPERATURES | Non-Final OA | SEEGENE, INC. |
| 18515013 | REVERSIBLY CROSS-LINKED HYDROGELS, AND METHODS OF USING THE SAME FOR CLUSTER AMPLIFICATION | Final Rejection | Illumina, Inc. |
| 18606513 | COMPOSITION OF TRANSFER RNAS AND USE IN PRODUCTION OF PROTEINS CONTAINING NON-STANDARD AMINO ACIDS | Non-Final OA | Absci Corporation |
| 17240865 | EXPONENTIAL BASE-3 AND GREATER NUCLEIC ACID AMPLIFICATION WITH CYCLING PROBE | Non-Final OA | Cepheid |
| 18000615 | MULTI-SENSING OF NUCLEIC ACID AND SMALL MOLECULE MARKERS | Non-Final OA | LogicInk Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy